The leading position of PJSC Kraspharma in the Russian pharmaceutical market is the result of the dedicated efforts of all the company’s divisions. Undoubtedly, competitive advantages are achieved primarily through the quality and accessibility of our products — tangible assets that generate profit. However, no less important is the stable growth and reputation of the company, which are defined by the transparency of our business, making Kraspharma an attractive investment opportunity.
PJSC «Kraspharma» is a leading Russian pharmaceutical company and a manufacturer of hospital medications. The product portfolio of «Kraspharma» includes parenteral antibiotics in the forms of "powder for preparing an injection solution," "lyophilisate for preparing an injection solution," antituberculosis drugs, fibrinolysis inhibitors (hemostatic agents), osmotic diuretics, as well as a wide range of infusion solutions, including those used for restoring electrolyte balance, anti-shock fluids, and detoxifying solutions. PJSC «Kraspharma» is a publicly traded company and adheres to advanced corporate governance standards and information disclosure practices. The company’s shares are listed on the Russian stock exchange. With a continuous focus on improving corporate policies and enhancing information transparency, we strive to provide our investors and shareholders with comprehensive data on the company’s activities, ensuring accessibility and ease of use of the information.
Share
